With the soon-to-be approved novel pharmacotherapies for geographic atrophy (GA) in Europe, clinics and hospitals need to re-think the management of patients who will be eligible for these new treatments. Patients with geographic atrophy are even more in numbers compared to those with wet AMD, and a significant increase in the demand for intravitreal injections is expected. It is therefore important to look at the clinical experience of the US, where these drugs are already available, and be prepared for potentially new models of patient flow management.

In this video Paolo Lanzetta, MD speaks with Baruch D. Kuppermann, MD, PhD of the University of California, Irvine. Professor Kuppermann shares his experience, and gives some useful pieces of advice to European retina specialists.